Foxp3 expression in human cancer cells
© Karanikas et al; licensee BioMed Central Ltd. 2008
Received: 15 October 2007
Accepted: 22 April 2008
Published: 22 April 2008
Transcription factor forkhead box protein 3 (Foxp3) specifically characterizes the thymically derived naturally occurring regulatory T cells (Tregs). Limited evidence indicates that it is also expressed, albeit to a lesser extent, in tissues other than thymus and spleen, while, very recently, it was shown that Foxp3 is expressed by pancreatic carcinoma. This study was scheduled to investigate whether expression of Foxp3 transcripts and mature protein occurs constitutively in various tumor types.
Materials and methods
Twenty five tumor cell lines of different tissue origins (lung cancer, colon cancer, breast cancer, melanoma, erythroid leukemia, acute T-cell leukemia) were studied. Detection of Foxp3 mRNA was performed using both conventional RT-PCR and quantitative real-time PCR while protein expression was assessed by immunocytochemistry and flow cytometry, using different antibody clones.
Foxp3 mRNA as well as Foxp3 protein was detected in all tumor cell lines, albeit in variable levels, not related to the tissue of origin. This expression correlated with the expression levels of IL-10 and TGFb1.
We offer evidence that Foxp3 expression, characterizes tumor cells of various tissue origins. The biological significance of these findings warrants further investigation in the context of tumor immune escape, and especially under the light of current anti-cancer efforts interfering with Foxp3 expression.
The transcription factor forkhead box protein 3 (Foxp3) is considered to be a master control gene of the function of thymically derived naturally occurring regulatory T cells (Tregs) . Due to the Tregs lineage specification by Foxp3, its tissue expression primarily by lymphoid tissues (thymus, spleen and lymph nodes) is expected and it has been well documented [1, 2]. Despite, however, the scarcity of information, Foxp3 expression by other normal tissues has also been observed, albeit to a far lesser extent . Moreover, induction of Foxp3 expression can occur intrinsically in peripheral Foxp3- T cells , while peripheral activated CD4+CD25- and CD8+CD25- T cells can acquire a regulatory function by expressing Foxp3 [5, 6]. Since the factors inducing Foxp3 expression in the above T cell populations remain unknown, we hypothesized that a similar induction could take place in other types of cells such as tumor cells. In support of the above, a very recent publication describes the expression of Foxp3 in pancreatic carcinoma cells providing evidence that this could be an important tumor escape mechanism . To this end, this study was scheduled to investigate whether expression of Foxp3 transcripts and mature protein is confined to pancreatic carcinoma or can occur constitutively in other tumor types as well as whether it might be repressed as a result of promoter hypermethylation, as is the case with several other genes including many associated with a tumor suppressor function . We provide unequivocal evidence that Foxp3 is expressed both at the transcript and protein level by tumor cells of various types.
Materials and methods
Cancer cell lines used in the study.
Cancer cell lines
Type of cancer
CALU-1, CALU-6, GILI, ONET, SK-LU-1, NCI-H441, NCI-H460, NCI-H596, NCI-H661, NCI-H520, PGEGE, PKAKI, PINTZ
HCA 2.6, HCA 3.2
MCF7, T47D, HBL-100p40, BT20, MDAMB231
GERL, DAJU 2.7, MEL272,
Acute T cell leukemia
To explore whether the expression of Foxp3 by cancer cells is affected by culture with the HITES solution, experiments were undertaken using parallel cultures of tumor cell lines, in the presence and in the absence of HITES solution, i.e. at corticosteroid concentrations used to inhibit development of lymphocytes, for a period of 3 weeks, allowing at least 10–12 cell divisions. All experiments were repeated three times.
Foxp3 mRNA expression
Foxp3 mRNA expression was examined in all cases using both conventional PCR (RT-PCR) and quantitative real-time PCR (qRT-PCR), after total RNA isolation from the tumor cell lines and reverse transcription to cDNA, as previously described , qRT-PCR was performed using the automated thermocycler RotorGene 6000 (Corbett Life Science, Sydney, Australia), the SYBR Supermix kit (Invitrogen, Paisley UK) and the RT2 PCR Primer Set for Foxp3 (SuperArray, USA). β2-Microglobulin (β2-M) was used as a reference gene (RT2 PCR Primer Set, SuperArray) [12, 13]. The qRT-PCR thermocycling conditions for Foxp3 were: 10 min at 95°C initial hold, followed by 40 cycles of denaturation at 95°C, annealing at 60°C and extension at 72°C all for 15 sec. The qRT-PCR thermocycling conditions for β2-M were: 10 min at 95°C initial hold, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing/extension at 60°C for 60 sec. Relative expression was analyzed using the Rotor Gene software (Ver. 6) and is presented as a multiple of the gene expression in one fibroblast line isolated during the development of the cancer cell lines. EBV-transformed B cells were used as negative controls, whereas a CD4+ Treg clone (kindly provided by Sophie Lucas, Brussels, Belgium) and PHA blasts were used as positive controls. For RT-PCR amplifications, 20 μM of the following primer sets were used for β-actin, forward 5' GGCATCGTGATGGACTCCG 3' and reverse 5' GCTGGAAGGTGGACAGCGA 3' and the RT2 PCR Primer Set for Foxp3 (SuperArray), in a total reaction volume of 25 μL. Thermocycling conditions (PTC-200, MJ Research, Watertown-Mass., USA) included for β-actin 21 cycles of denaturation at 94°C, annealing at 68°C and extension at 72°C, all for 1 min, and for Foxp3, 31 cycles of denaturation at 95°C, annealing at 60°C and extension at 72°C, all for 15 sec.
IL-10 and TGFb1 mRNA expression
IL-10 and TGFb1 mRNA expression was examined using both conventional PCR (RT-PCR) for IL-10 and quantitative real-time PCR (qRT-PCR) for TGFb1 using cDNA prepared as above. For TGFb1, the RT2 PCR Primer Set from SuperArray was used, and the qRT-PCR thermocycling conditions were: 10 min at 95°C initial hold, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 60 sec. β2-M was used as a reference gene as for Foxp3 and the relative expression was analyzed and presented as above. For RT-PCR amplifications of IL-10, 20 μM of the RT2 PCR Primer Set for IL-10 (SuperArray) was used in a total reaction volume of 25 μL. Thermocycling conditions included 30 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 15 sec and extension at 72°C for 30 sec. IL-10 expression is presented as a semiquantitative measurement obtained by calculating the intensity quotient for the gene and β-ac tin  and then normalizing to that of a fibroblast cell line.
Foxp3 protein expression
To determine whether the expression of Foxp3 mRNA results in the production of a mature protein, tumor cell lines were examined by immunohistochemistry and by flow cytometry for intracellular expression of Foxp3, using different antibody clones. Immunostaining was performed according to a previously published protocol with slight modifications . Sections were fixed in 4% paraformaldehyde, blocked in 5% normal mouse serum (eBioscience), and incubated with a mouse monoclonal biotinylated anti-Foxp3 antibody against the amino terminus of the human Foxp3 protein (dilution 1/250) (clone 236A/E7, eBioscience, San Diego, USA), followed by goat anti-mouse secondary antibody and dextran coupled with peroxidase molecules (EnVision Detection System, Peroxidase/DAB, Rabbit/Mouse, Dako). DAB (EnVision Detection System, Dako) was used as peroxidase substrate, while endogenous peroxidase activity was blocked directly after the fixation step with 1% of H2O2 in 1xTBS. Sections were counterstained with Mayer hematoxylin (Merck).
Flow cytometric detection of intracellular Foxp3 expression was performed using an anti-Foxp3 monoclonal antibody (clone PCH101, eBioscience) labeled with phycoerythrin and the corresponding IgG2a isotypic antibody according to the manufacturer. In each analysis, approximately 106 tumor cells were used, and approximately 50–100 × 103 events were acquired and analyzed on the basis of Foxp3 positivity using the CXP program (Beckman Coulter, USA). Positivity was determined on the basis of the Mean Fluorescence Index (MFI) for staining with Foxp3, against the staining observed with the corresponding isotypic antibody.
Expression values are presented as raw values or as mean ± SD. Spearman's bivariate correlation was used to identify correlations (Pearson's correlation and significance is presented) with the statistical software SPSS for Windows (version 11.5).
Results and discussion
Corticosteroids significantly increase Foxp3-as well as IL10- mRNA expression in un-stimulated peripheral blood CD4+ T cells . No difference in Foxp3 mRNA expression levels was detected when cancer cell lines (n = 3) were cultured with or without HITES, for a period of 3 weeks (10–12 cell divisions). This difference between cancer cells and CD4+ T cells might represent a mechanism utilized by the first to escape from corticosteroid-regulated death mediated by GITR as it happens in T cells .
Following the recent finding that Foxp3 is expressed by pancreatic carcinoma cells , our study clearly demonstrates that its expression is not restricted to this particular type of tumor but seems to characterize many other tumors not only of epithelial (e.g. lung, breast, colon) but also of other tissue origins (melanoma, leukemia). Whether Foxp3 expression by tumor cells is directly related to carcinogenesis or results indirectly by activation of its normally silent gene, is questionable. Fibroblasts used as controls in our study exhibited insignificant levels of Foxp3 transcripts that is in accordance to the results of Hinz et al  showing no Foxp3 expression by normal pancreatic duct epithelial cells. However, Christodoulou et al  have shown that normal salivary gland epithelial cells express Foxp3 mRNA, as did three neoplastic lines of epithelial origin, but not human umbilical vein endothelial cells. Foxp3 induction pathways (e.g. those of IFN-γ, TLRs and others) that, along with the TcR-mediated one, are functioning in Tregs , could be implicated in cancer and/or transforming cells. In fact, the recently shown induction by TGF-β  seems to be a key facet of the complex role of TGF-β in cancer biology .
The varying levels of Foxp3 mRNA expression detected in tumor cells raises a serious issue concerning the use of the detection of Foxp3 mRNA expression in surgical tumor samples as an index of tumor infiltration by Tregs [23–25]. Thereby, conclusions derived from such studies about the relationship between Tregs and cancer might be misleading [26, 27]. This variation however, might also imply a different role for Foxp3 expression by tumor cells. A recent finding in breast cancer cells proposes Foxp3 as an important suppressor for human breast cancer . Functional somatic mutations, and down-regulation of the FOXP3 gene, were commonly found in human breast cancer samples and although this also correlated with HER-2/ErbB2 overexpression it was clearly lower than that of normal breast tissue . Whether the presence of such mutations could account for the very low expression levels observed with some tumor lines in our study remains to be investigated as does confirmation that Foxp3 is a tumor suppressor molecule.
Based on the finding that Foxp3 expression by pancreatic carcinoma results in inhibition of proliferation and possibly not of activation of naïve CD4+ CD25- T cells, Hinz et al  propose that this might represent a tumor escape mechanism. Our results, however, uncovering Foxp3 expression as a generalized feature of tumor cells, indicate that the determination of its functional consequences requires further elucidation, especially in the context of current anti-cancer efforts to control the pathogenetic action of Tregs, mainly those interfering with Foxp3 expression .
This study provides clear evidence that cancer cells of various types express a transcript for Foxp3 as well as the mature protein. This finding can be of utmost significance under the light of Tregs being implicated in carcinogenesis and ongoing efforts towards the development of anticancer approaches specifically inhibiting the expression and/or function of Foxp3 by tumor-associated Tregs
We acknowledge the kind provision of cancer cell lines by Prof P Coulie (Universite Catholique Du Louvain, Brussels, Belgium), and Prof B Loveland (Austin Research Institute, Melbourne, Australia). The CD4+ Treg clone was kindly donated by Dr S Lucas (Universite Catholique Du Louvain, Brussels, Belgium). Vaios Karanikas is a recipient of a Marie Curie Incoming International Fellow (Contract MIF1-CT-2006-021795). Fani Kalala is a recipient of a Glaxo Smith Kline Hellas, Research Fellowship (Program 3116). This work was supported in part by grant provided by the Hellenic General secretariat for Research and Technology (EPAN 18.104.22.168, 05NON-EU-445) and a European Community grant (FP6 Contract MIRG-CT-2006-046459, IMMUNOEPIGENETICS). The authors declare that they have no competing interests.
- Hori S, Sakaguchi S: Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 2004, 6: 745-751. 10.1016/j.micinf.2004.02.020.View ArticlePubMedGoogle Scholar
- Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001, 27: 68-73. 10.1038/83784.View ArticlePubMedGoogle Scholar
- T1DBase – Tissue Specific Expression Data. Accessed August. 1, 2007, [http://www.t1dbase.org/page/TissueHome]
- Ahmadzadeh M, Antony PA, Rosenberg SA: IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother. 2007, 30: 294-302. 10.1097/CJI.0b013e3180336787.PubMed CentralView ArticlePubMedGoogle Scholar
- Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, van Landeghen M, Buckner JH, Ziegler SF: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest. 2003, 112: 1437-1443.View ArticlePubMedGoogle Scholar
- Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, Zanden van der L, de Vries RR, Huizinga TW, Ottenhoff TH, Toes RE: Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol. 2005, 66: 13-20. 10.1016/j.humimm.2004.05.016.View ArticlePubMedGoogle Scholar
- Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, Klöppel G, Kabelitz D, Kalthoff H: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007, 67: 8344-8350. 10.1158/0008-5472.CAN-06-3304.View ArticlePubMedGoogle Scholar
- Esteller M: Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 2005, 45: 629-656. 10.1146/annurev.pharmtox.45.120403.095832.View ArticlePubMedGoogle Scholar
- Sugaya M, Takenoyama M, Osaki T, Yasuda M, Nagashima A, Sugio K, Yasumoto K: Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002, 122: 282-288. 10.1378/chest.122.1.282.View ArticlePubMedGoogle Scholar
- Carney DN, Bunn PAJ, Gazdar AF, Pagan JA, Minna JD: Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci USA. 1981, 78: 3185-3189. 10.1073/pnas.78.5.3185.PubMed CentralView ArticlePubMedGoogle Scholar
- Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI, Germenis AE: Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther. 2007, 6 (8): 1258-1262.View ArticlePubMedGoogle Scholar
- Blanquicett C, Johnson MR, Heslin M, Diasio RB: Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues : Applications in pharmacogenomic gene expression studies. Anal Biochem. 2002, 303: 209-214. 10.1006/abio.2001.5570.View ArticlePubMedGoogle Scholar
- Morse DL, Carroll D, Weberg L, Borgstrom MC, Ranger-Moore J, Gillies RJ: Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem. 2005, 342: 69-77. 10.1016/j.ab.2005.03.034.View ArticlePubMedGoogle Scholar
- Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG: Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 2000, 60: 4855-63.PubMedGoogle Scholar
- Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D: In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med. 2006, 4: 52-10.1186/1479-5876-4-52.PubMed CentralView ArticlePubMedGoogle Scholar
- Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, Levine SS, Fraenkel E, von Boehmer H: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007, 445: 931-935. 10.1038/nature05478.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006, 126: 375-387. 10.1016/j.cell.2006.05.042.View ArticlePubMedGoogle Scholar
- Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt-Weber CB: Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004, 114: 1425-1433. 10.1016/j.jaci.2004.07.014.View ArticlePubMedGoogle Scholar
- Riccardi C, Cifone MG, Migliorati G: Glucocorticoid hormone-induced modulation of gene expression and regulation of T-cell death: role of GITR and GILZ, two dexamethasone-induced genes. Cell Death Differ. 1999, 6: 1182-1189. 10.1038/sj.cdd.4400609.View ArticlePubMedGoogle Scholar
- Christodoulou MI, Moutsopoulos NM, Kapsogeorgou EK: OXP3 transcription factor is not confined to regulatory T (Treg) cells: Human epithelial cells express FOXP3 mRNA. Ann Rheum Dis. 2006, 65 (suppl 1): FA5-Google Scholar
- Zhang L, Zhao Y: The regulation of Foxp3 expression in regulatory CD4(+) CD25 (+) T cells: Multiple pathways on the road. J Cell Physiol. 2007, 211: 590-597. 10.1002/jcp.21001.View ArticlePubMedGoogle Scholar
- Prud'Homme GJ: Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 2007, doi: 10.1038/labinvest.3700669Google Scholar
- Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10: 942-949. 10.1038/nm1093.View ArticlePubMedGoogle Scholar
- Wolf Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005, 11: 8326-8331. 10.1158/1078-0432.CCR-05-1244.View ArticleGoogle Scholar
- Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED: Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007, 13: 2075-2081. 10.1158/1078-0432.CCR-06-2139.View ArticlePubMedGoogle Scholar
- Knutson KL, Disis ML, Salazar LG: CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2007, 56: 271-285. 10.1007/s00262-006-0194-y.View ArticlePubMedGoogle Scholar
- Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.View ArticlePubMedGoogle Scholar
- Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang CY, Zheng P, Liu Y: FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007, 129: 1275-1286. 10.1016/j.cell.2007.04.034.PubMed CentralView ArticlePubMedGoogle Scholar
- Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E: Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007, 67: 371-380. 10.1158/0008-5472.CAN-06-2903.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.